PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
Conference Call and Webcast at 8:30 AM Eastern Time
美國東部時間上午 8:30 的電話會議和網絡直播
NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, May 14, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's first quarter 2024 financial results.
紐約，2024 年 5 月 3 日 /PRNewswire/-- PavMed Inc. 納斯達克股票代碼：PAVM、PAVMZ）（“PAVMed” 或 “公司”）是一家多元化的商業階段醫療技術公司，在醫療器械、診斷和數字醫療領域開展業務。該公司今天宣佈，它將在美國東部時間2024年5月14日星期二上午8點30分舉辦業務最新情況電話會議和網絡直播。在電話會議上，PavMed董事長兼首席執行官Lishan Aklog醫學博士將提供業務最新情況，包括公司的運營和增長戰略概述。此外，PAVMed總裁兼首席財務官丹尼斯·麥格拉思將討論公司2024年第一季度的財務業績。
The webcast will be available at the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "PAVmed Business Update" to join.
該網絡直播將在公司網站pavmed.com的投資者關係部分播出。或者，要通過電話參加電話會議，美國的來電者應撥打1-800-836-8184，國際聽衆應撥打1-646-357-8785。所有聽衆都應向運營商提供電話會議名稱 “PavMed 業務更新” 以加入。
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.
電話會議結束後，公司網站pavmed.com的投資者關係部分將提供爲期30天的重播。
About PAVmed
關於 PAVMed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Lucid Diagnostics Inc., is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other majority-owned subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.
PavMed Inc. 是一家多元化的商業階段醫療技術公司，業務涉及醫療器械、診斷和數字醫療領域。其控股子公司Lucid Diagnostics Inc. 是一家商業階段的癌症預防醫療診斷公司，負責銷售ESOGuard 食管 DNA 測試和 ESOCheck 食管細胞收集設備——第一個也是唯一一個廣泛早期發現食道癌前病變以降低食道癌死亡風險的商業工具。其另一家控股子公司Veris Health Inc. 是一家數字健康公司，專注於通過使用具有無線通信功能的植入式生物傳感器以及定製的連接外部設備套件進行遠程患者監測，從而增強個性化癌症護理。Veris正在同時開發一種可植入的生理監護儀，該監護儀可與化療端口一起植入，它將與Veris癌症護理平台接口。
For more information about PAVmed, please visit pavmed.com.
有關 PavMed 的更多信息，請訪問 pavmed.com。
For more information about Lucid Diagnostics, please visit luciddx.com.
有關 Lucid Diagnostics 的更多信息，請訪問 luciddx.com。
For more information about Veris Health, please visit verishealth.com.
有關 Veris Health 的更多信息，請訪問 verishealth.com。
SOURCE PAVmed Inc.
來源 PavMed Inc.